<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00618540</url>
  </required_header>
  <id_info>
    <org_study_id>2007UC002</org_study_id>
    <secondary_id>UMN-0612M98407</secondary_id>
    <secondary_id>LCH-HCT-2006</secondary_id>
    <secondary_id>UMN-MT2006-07</secondary_id>
    <nct_id>NCT00618540</nct_id>
  </id_info>
  <brief_title>Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis</brief_title>
  <official_title>Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving a monoclonal antibody, such as alemtuzumab, and chemotherapy drugs, such as
      fludarabine and melphalan, before a donor stem cell transplant helps stop the patient's
      immune system from rejecting the donor's stem cells and helps stop the growth of abnormal
      cells. When the healthy stem cells from a donor are infused into the patient they may help
      the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
      Sometimes the transplanted cells from a donor can make an immune response against the body's
      normal cells. Giving cyclosporine and mycophenolate mofetil before and after transplant may
      stop this from happening.

      PURPOSE: This phase II trial is studying how well giving alemtuzumab together with
      fludarabine and melphalan followed by a donor stem cell transplant works in treating young
      patients with resistant Langerhans cell histiocytosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the overall and disease-free survival of poor-risk pediatric patients with
           Langerhans cell histiocytosis at 1 and 3 years after reduced-intensity hematopoietic
           cell transplantation (RI-HCT).

      Secondary

        -  To determine day 100 transplantation-related mortality.

        -  To determine the incidence of hematopoietic recovery and chimerism at day 100 and at 1
           year post RI-HCT.

        -  To determine the incidence of grades II-IV and III-IV acute graft-versus-host disease
           (GVHD).

        -  To determine the incidence of chronic GVHD.

      OUTLINE: This is a multicenter study.

        -  Non-myeloablative conditioning: Patients receive alemtuzumab intravenously (IV) over 2
           hours on days -8 to -4, fludarabine phosphate IV over 30-60 minutes on days -7 to -3,
           and melphalan IV over 15-30 minutes on day -2. Some patients may receive anti-thymocyte
           globulin IV on days -6 to -2 instead of alemtuzumab.

        -  Graft-versus-host disease prophylaxis and immunosuppression: Patients receive
           cyclosporine A (CSA) IV or orally 2-3 times daily beginning on day -3 and continuing
           until day 50 post transplantation, followed by a taper over 8 weeks in the absence of
           GVHD or donor lymphocyte infusion given for decreasing donor chimerism. Patients with
           mismatched donors (any source) and those receiving peripheral blood stem cells also
           receive mycophenolate mofetil (MMF) IV or orally 2-3 times daily beginning on day -3 and
           continuing to day 30 or 7 days after engraftment, whichever day is later, in the absence
           of GVHD. In patients with acute GVHD requiring systemic therapy, Mycophenolate mofetil
           (MMF) may be stopped 7 days after initiation of systemic therapy.

        -  Allogeneic hematopoietic stem cell infusion: Patients undergo infusion of bone marrow
           (preferred) or peripheral blood stem cells on day 0. Patients also receive filgrastim
           (G-CSF) subcutaneously or IV beginning on day 8 and continuing until blood counts
           recover for 2 consecutive days.

        -  Donor lymphocyte infusion (DLI): Patients with mixed chimerism (i.e., &lt; 95% donor) and
           those with &lt; 50% donor T-cell engraftment at any engraftment assessment time point are
           eligible for DLI, in the absence of GVHD. If mixed chimerism persists, escalating doses
           of CD3-positive lymphocytes are administered every 3-4 weeks, in the absence of GVHD.

      After completion of study therapy, patients are followed from engraftment through day 100,
      and then at 6 months, 1 year, and annually thereafter for 2-5 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual
  </why_stopped>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Year 1, Year 3</time_frame>
    <description>Count of patients alive at 1 and 3 years. Deaths from any cause are events. Surviving patients are censored at the date of last contact.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free Survival at 12 Months Post Transplantation</measure>
    <time_frame>Year 1</time_frame>
    <description>This outcome is defined as survival with resolution of LCH at 12 months post transplant.
Unresolved disease for over 12 months post-transplant, progressive disease after this time period, recurrence of disease and death from any cause are considered events.
Those who survive with resolution of disease are censored at the date of last contact.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transplantation-related Death</measure>
    <time_frame>Day 100</time_frame>
    <description>Count of patients who died by day 100 related to the transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil Engraftment</measure>
    <time_frame>Day 100</time_frame>
    <description>Incidence of neutrophil recovery and donor chimerism at Day 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade II-IV Acute Graft-versus-host-disease (GVHD)</measure>
    <time_frame>Day 100 and Month 6</time_frame>
    <description>The occurrence of skin, gastrointestinal or liver abnormalities fulfilling the criteria of Grades II, III and/or IV acute GVHD are considered events (Appendix II). Patients without acute GvHD will be censored at the time of death or last follow-up. Patients that survive &lt;21 days and listed as not evaluable will be excluded. Patients receiving a second transplant will be censored at the time of second transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Chronic GVHD</measure>
    <time_frame>Day 100 and Month 6</time_frame>
    <description>Occurrence of symptoms in any organ system fulfilling the criteria of limited or extensive chronic GvHD (Appendix III), among patients surviving &gt; 90 days with evidence of engraftment. Patients without chronic GvHD will be censored at time of death or last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Engraftment</measure>
    <time_frame>Day 100</time_frame>
    <description>Incidence of platelet recovery and donor chimerism at Day 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade III-IV Acute Graft-versus-host-disease (GVHD)</measure>
    <time_frame>Day 100 and Month 6</time_frame>
    <description>The occurrence of skin, gastrointestinal or liver abnormalities fulfilling the criteria of Grades II, III and/or IV acute GVHD are considered events (Appendix II). Patients without acute GvHD will be censored at the time of death or last follow-up. Patients that survive &lt;21 days and listed as not evaluable will be excluded. Patients receiving a second transplant will be censored at the time of second transplant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Histiocytosis, Langerhans-cell</condition>
  <arm_group>
    <arm_group_label>Alemtuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients administered with alemtuzumab, fludarabine phosphate, melphalan and donor stem cell transplantation in children with resistant Langerhans cell histiocytosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alemtuzumab</intervention_name>
    <description>Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.</description>
    <arm_group_label>Alemtuzumab</arm_group_label>
    <other_name>Campath(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3. (dose adjust if age &lt;12 months)</description>
    <arm_group_label>Alemtuzumab</arm_group_label>
    <other_name>Fludara(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age &lt;12 months)</description>
    <arm_group_label>Alemtuzumab</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>stem cell transplantation</intervention_name>
    <description>Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation</description>
    <arm_group_label>Alemtuzumab</arm_group_label>
    <other_name>Stem cell transplant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed Langerhans cell histiocytosis (LCH) by demonstration of CD1a
             positivity or Birbeck granules in lesions

          -  Considered poor-risk, defined as multisystem disease with involvement of one or more
             risk organs (i.e., liver, spleen, lungs, and/or hematopoietic system)

               -  No isolated &quot;lung only&quot; LCH

          -  Progressive disease after one of the following treatments:

               -  LCH-III protocol or other standard LCH-directed therapies

               -  At least 1 course of the current salvage protocol (i.e., LCH-2 2005) or similar
                  therapy (e.g., cytosine arabinoside or cladribine-based regimens)

          -  HLA-matched related or unrelated donor OR unrelated umbilical cord blood (UCB)
             available

               -  1 locus mismatch for donor allowed

               -  Up to 2 loci mismatch for unrelated UCB allowed

          -  Any hematologic status (transfusion support allowed)

          -  Adequate hepatic, renal, cardiac, and pulmonary function to undergo reduced-intensity
             hematopoietic cell transplantation (RI-HCT) including the following:

               -  Transaminases &lt; 5 times upper limit of normal (ULN)

               -  Bilirubin &lt; 3 times ULN (unless secondary to hepatic LCH)

               -  Creatinine ≤ 2 mg/dL (adults) (if creatinine &gt; 1.2 OR history of renal
                  dysfunction, must have estimated creatinine clearance &gt; 40 mL/min)

               -  Creatinine clearance &gt; 40 mL/min (pediatrics)

               -  Glomerular filtration rate ≥ 50mL/min

          -  Negative pregnancy test

        Exclusion Criteria:

          -  Decompensated congestive heart failure, uncontrolled arrhythmia, or left ventricular
             ejection fraction ≥ 35%

          -  Pulmonary failure (i.e., requiring mechanical ventilation) unless secondary to active
             underlying LCH

          -  Isolated liver sclerosis or pulmonary fibrosis unless secondary to active underlying
             LCH

          -  Uncontrolled active life-threatening infection

          -  Pregnant or nursing

          -  Less than 4 weeks after last attempted salvage chemotherapy treatment

          -  Other concurrent chemotherapy agents (e.g., methotrexate) during entire
             transplantation period up to day 100 post-transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Smith</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2008</study_first_submitted>
  <study_first_submitted_qc>February 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2008</study_first_posted>
  <results_first_submitted>April 22, 2015</results_first_submitted>
  <results_first_submitted_qc>October 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 3, 2015</results_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>childhood Langerhans cell histiocytosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histiocytosis</mesh_term>
    <mesh_term>Histiocytosis, Langerhans-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Alemtuzumab Conditioning</title>
          <description>Patients administered with alemtuzumab, fludarabine phosphate, melphalan and donor stem cell transplantation in children with resistant Langerhans cell histiocytosis.
alemtuzumab: Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
fludarabine phosphate: Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3.
(dose adjust if age &lt;12 months)
melphalan: Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age &lt;12 months)
stem cell transplantation: Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alemtuzumab Conditioning</title>
          <description>Patients administered with alemtuzumab, fludarabine phosphate, melphalan and donor stem cell transplantation in children with resistant Langerhans cell histiocytosis.
alemtuzumab: Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
fludarabine phosphate: Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3.
(dose adjust if age &lt;12 months)
melphalan: Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age &lt;12 months)
stem cell transplantation: Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Count of patients alive at 1 and 3 years. Deaths from any cause are events. Surviving patients are censored at the date of last contact.</description>
        <time_frame>Year 1, Year 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab Conditioning</title>
            <description>Patients administered with alemtuzumab, fludarabine phosphate, melphalan and donor stem cell transplantation in children with resistant Langerhans cell histiocytosis.
alemtuzumab: Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
fludarabine phosphate: Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3.
(dose adjust if age &lt;12 months)
melphalan: Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age &lt;12 months)
stem cell transplantation: Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Count of patients alive at 1 and 3 years. Deaths from any cause are events. Surviving patients are censored at the date of last contact.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease-free Survival at 12 Months Post Transplantation</title>
        <description>This outcome is defined as survival with resolution of LCH at 12 months post transplant.
Unresolved disease for over 12 months post-transplant, progressive disease after this time period, recurrence of disease and death from any cause are considered events.
Those who survive with resolution of disease are censored at the date of last contact.</description>
        <time_frame>Year 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab Conditioning</title>
            <description>Patients administered with alemtuzumab, fludarabine phosphate, melphalan and donor stem cell transplantation in children with resistant Langerhans cell histiocytosis.
alemtuzumab: Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
fludarabine phosphate: Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3.
(dose adjust if age &lt;12 months)
melphalan: Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age &lt;12 months)
stem cell transplantation: Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival at 12 Months Post Transplantation</title>
          <description>This outcome is defined as survival with resolution of LCH at 12 months post transplant.
Unresolved disease for over 12 months post-transplant, progressive disease after this time period, recurrence of disease and death from any cause are considered events.
Those who survive with resolution of disease are censored at the date of last contact.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transplantation-related Death</title>
        <description>Count of patients who died by day 100 related to the transplantation.</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab Conditioning</title>
            <description>Patients administered with alemtuzumab, fludarabine phosphate, melphalan and donor stem cell transplantation in children with resistant Langerhans cell histiocytosis.
alemtuzumab: Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
fludarabine phosphate: Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3.
(dose adjust if age &lt;12 months)
melphalan: Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age &lt;12 months)
stem cell transplantation: Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Transplantation-related Death</title>
          <description>Count of patients who died by day 100 related to the transplantation.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutrophil Engraftment</title>
        <description>Incidence of neutrophil recovery and donor chimerism at Day 100.</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab Conditioning</title>
            <description>Patients administered with alemtuzumab, fludarabine phosphate, melphalan and donor stem cell transplantation in children with resistant Langerhans cell histiocytosis.
alemtuzumab: Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
fludarabine phosphate: Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3.
(dose adjust if age &lt;12 months)
melphalan: Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age &lt;12 months)
stem cell transplantation: Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Neutrophil Engraftment</title>
          <description>Incidence of neutrophil recovery and donor chimerism at Day 100.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grade II-IV Acute Graft-versus-host-disease (GVHD)</title>
        <description>The occurrence of skin, gastrointestinal or liver abnormalities fulfilling the criteria of Grades II, III and/or IV acute GVHD are considered events (Appendix II). Patients without acute GvHD will be censored at the time of death or last follow-up. Patients that survive &lt;21 days and listed as not evaluable will be excluded. Patients receiving a second transplant will be censored at the time of second transplant.</description>
        <time_frame>Day 100 and Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab Conditioning</title>
            <description>Patients administered with alemtuzumab, fludarabine phosphate, melphalan and donor stem cell transplantation in children with resistant Langerhans cell histiocytosis.
alemtuzumab: Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
fludarabine phosphate: Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3.
(dose adjust if age &lt;12 months)
melphalan: Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age &lt;12 months)
stem cell transplantation: Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grade II-IV Acute Graft-versus-host-disease (GVHD)</title>
          <description>The occurrence of skin, gastrointestinal or liver abnormalities fulfilling the criteria of Grades II, III and/or IV acute GVHD are considered events (Appendix II). Patients without acute GvHD will be censored at the time of death or last follow-up. Patients that survive &lt;21 days and listed as not evaluable will be excluded. Patients receiving a second transplant will be censored at the time of second transplant.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Chronic GVHD</title>
        <description>Occurrence of symptoms in any organ system fulfilling the criteria of limited or extensive chronic GvHD (Appendix III), among patients surviving &gt; 90 days with evidence of engraftment. Patients without chronic GvHD will be censored at time of death or last follow-up.</description>
        <time_frame>Day 100 and Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab Conditioning</title>
            <description>Patients administered with alemtuzumab, fludarabine phosphate, melphalan and donor stem cell transplantation in children with resistant Langerhans cell histiocytosis.
alemtuzumab: Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
fludarabine phosphate: Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3.
(dose adjust if age &lt;12 months)
melphalan: Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age &lt;12 months)
stem cell transplantation: Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Chronic GVHD</title>
          <description>Occurrence of symptoms in any organ system fulfilling the criteria of limited or extensive chronic GvHD (Appendix III), among patients surviving &gt; 90 days with evidence of engraftment. Patients without chronic GvHD will be censored at time of death or last follow-up.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Engraftment</title>
        <description>Incidence of platelet recovery and donor chimerism at Day 100.</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab</title>
            <description>Patients administered with alemtuzumab, fludarabine phosphate, melphalan and donor stem cell transplantation in children with resistant Langerhans cell histiocytosis.
alemtuzumab: Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
fludarabine phosphate: Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3.
(dose adjust if age &lt;12 months)
melphalan: Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age &lt;12 months)
stem cell transplantation: Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Engraftment</title>
          <description>Incidence of platelet recovery and donor chimerism at Day 100.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grade III-IV Acute Graft-versus-host-disease (GVHD)</title>
        <description>The occurrence of skin, gastrointestinal or liver abnormalities fulfilling the criteria of Grades II, III and/or IV acute GVHD are considered events (Appendix II). Patients without acute GvHD will be censored at the time of death or last follow-up. Patients that survive &lt;21 days and listed as not evaluable will be excluded. Patients receiving a second transplant will be censored at the time of second transplant.</description>
        <time_frame>Day 100 and Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab Conditioning</title>
            <description>Patients administered with alemtuzumab, fludarabine phosphate, melphalan and donor stem cell transplantation in children with resistant Langerhans cell histiocytosis.
alemtuzumab: Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
fludarabine phosphate: Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3.
(dose adjust if age &lt;12 months)
melphalan: Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age &lt;12 months)
stem cell transplantation: Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grade III-IV Acute Graft-versus-host-disease (GVHD)</title>
          <description>The occurrence of skin, gastrointestinal or liver abnormalities fulfilling the criteria of Grades II, III and/or IV acute GVHD are considered events (Appendix II). Patients without acute GvHD will be censored at the time of death or last follow-up. Patients that survive &lt;21 days and listed as not evaluable will be excluded. Patients receiving a second transplant will be censored at the time of second transplant.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse event data were collected at 100 days post-transplantation.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Alemtuzumab Conditioning</title>
          <description>Patients administered with alemtuzumab, fludarabine phosphate, melphalan and donor stem cell transplantation in children with resistant Langerhans cell histiocytosis.
alemtuzumab: Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
fludarabine phosphate: Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3.
(dose adjust if age &lt;12 months)
melphalan: Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age &lt;12 months)
stem cell transplantation: Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory syncytial virus (RSV) infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Multiple systemic infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Angela Smith, MD</name_or_title>
      <organization>University of Minnesota, Pediatric BMT</organization>
      <phone>612-626-2778</phone>
      <email>smith719@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

